ArticleFrontiers in immunology2025

Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.

Nafeisha Simayi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.